Skip to main content
SpringerLink
Log in

Advanced diffuse malignant peritoneal mesothelioma responding to palliative chemotherapy

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

A 64-year-old man diagnosed with advanced malignant peritoneal mesothelioma by laparoscopic biopsy was treated with systemic chemotherapy. The patient underwent first-line chemotherapy with pemetrexed plus cisplatin for 11 months, then second-line chemotherapy with gemcitabine plus vinorelbine for 6 months, and third-line chemotherapy with CPT-11 for 4 months. After third-line chemotherapy failed, he received palliative treatment. Although the tumor continued to grow, and he died 24 months after initiation of treatment, chemotherapy prolonged the survival time and improved his quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636.

    Article  PubMed  CAS  Google Scholar 

  2. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980;303:200–2.

    Article  PubMed  CAS  Google Scholar 

  3. Rodríguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2009;99:51–7.

    Article  PubMed  Google Scholar 

  4. Fujimoto N, Aoe K, Gemba K, Kato K, Yamazaki K, Kishimoto T. Clinical investigation of malignant mesothelioma in Japan. J Cancer Res Clin Oncol. 2010;136:1755–9.

    Article  PubMed  Google Scholar 

  5. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981;8:313–20.

    PubMed  CAS  Google Scholar 

  6. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.

    Article  PubMed  Google Scholar 

  7. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–6.

    Article  PubMed  Google Scholar 

  8. Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, et al. Malignant peritoneal mesothelioma—results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–8.

    Article  PubMed  CAS  Google Scholar 

  9. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24:1443–8.

    Article  PubMed  CAS  Google Scholar 

  10. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19:370–3.

    Article  PubMed  CAS  Google Scholar 

  11. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26:3567–72.

    Article  PubMed  CAS  Google Scholar 

  12. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, et al. Second line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16:923–7.

    Article  PubMed  CAS  Google Scholar 

  13. Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555–61.

    Article  PubMed  CAS  Google Scholar 

  14. Kindler HL, Herndon JE, Zhang C, Cancer and Leukemia Group B. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005;48:423–8.

    Article  PubMed  Google Scholar 

  15. Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 2007;109:93–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki Hospital, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan

    Koji Nakashima, Haruhiko Inatsu, Kazuo Kitamura, Tomomi Hikosaka, Shinri Hoshiko & Shinya Ashiduka

Authors
  1. Koji Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haruhiko Inatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuo Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomomi Hikosaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinri Hoshiko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinya Ashiduka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Nakashima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakashima, K., Inatsu, H., Kitamura, K. et al. Advanced diffuse malignant peritoneal mesothelioma responding to palliative chemotherapy. Clin J Gastroenterol 5, 373–376 (2012). https://doi.org/10.1007/s12328-012-0334-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-012-0334-1

Keywords

Search

Navigation